HEALTHY EXTRACTS INC. acquires Gummy USA LLC (2025)

Deal facts

Buyer: HEALTHY EXTRACTS INC.
Target: Gummy USA LLC
Deal value: Not disclosed
Announced: 2 October 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

30 Sept 2025CompletedClosed
HEALTHY EXTRACTS INC. completes acquisition of Gummy USA LLC
Item 1.01 Entry into a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. Acquisition of Gummy USA LLC On July 19, 2025, we entered into a Membership Interest Purchase Agreement (the “MIPA”) with Gummy USA LLC (“GUSA”) and its sole-member, Donald Swanson (“Swanson”), pursuant to which we acquired one-hundred percent (100%) of the outstanding membership interes
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of Gummy USA LLC by Healthy Extracts Inc. announced on 2 October 2025. This is a strategic move within the healthcare sector, executed entirely through a share exchange. The fact that the deal is already completed suggests both parties moved with speed and certainty, likely having resolved any material commercial or regulatory hurdles before the announcement. In the US market, a pure share consideration deal often implies a strong alignment of long-term interests between the buyer and the target, as the founders and key stakeholders remain exposed to the future performance of the combined entity.

For the SME founder reading this, the structure of the transaction offers a specific lesson on how strategic buyers value growth. By choosing shares over cash, Healthy Extracts Inc. has effectively deferred the full cost of the acquisition and tied the payout to their own future success. This mechanism shifts the risk profile significantly. If the combined business struggles to integrate the gummy brand or fails to meet market expectations, the value of the consideration drops. Conversely, if the strategic fit delivers the anticipated synergies, the upside remains uncapped. This is distinct from a cash deal where the seller walks away with a fixed sum regardless of future integration success.

The absence of a disclosed value in the public record is not unusual for private US transactions, yet it highlights the importance of understanding the underlying mechanics. When a deal closes without a headline price, the focus must shift to the terms of the share exchange and the governance structure that follows. Founders must scrutinise the change-of-control covenants and the voting rights attached to the new shares. In the healthcare sector, where regulatory scrutiny from bodies like the FDA is constant, maintaining operational independence post-close can be difficult. The board composition and decision-making rights will define whether the target retains its identity or becomes a mere division.

You should review your current cap table and identify which shareholders hold the power to approve a share-based exit. If you are considering a strategic sale, insist on a detailed breakdown of the share exchange ratio and the specific vesting schedules attached to any retained equity before signing a term sheet.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More strategic acquisition deals More from HEALTHY EXTRACTS INC.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history